Physician profile
Ashraf Abusara
NPI 1265745715
$3,019.84
in general payments reported to CMS, 2019-2025
23 companies · $661 in 2025
The $661 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $358 · 2021: $165 · 2022: $476 · 2023: $536 · 2024: $551 · 2025: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,748.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $517.48 | 2019-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $417.82 | 2019-2025 | |
| Abbott Laboratories | $414.16 | 2023-2025 | Cardiomems, Mitraclip |
| E.R. Squibb & Sons, L.L.C. | $213.40 | 2022-2024 | Eliquis, Camzyos |
| Boston Scientific Corporation | $209.43 | 2020-2025 | Cds - Mct/Cem Monitoring, Bodyguardian |
| Philips North America LLC | $201.97 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $183.06 | 2022-2023 | Verquvo |
| Atricure, INC. | $171.67 | 2025 | Atricure Cryoice Cryoablation System (Cryo2), Atriclip Laa Exclusion System, Synergy Ablation System |
| Bayer Healthcare Pharmaceuticals INC. | $157.70 | 2025 | |
| Janssen Pharmaceuticals, INC | $132.13 | 2019-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $75.82 | 2024-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.22 | 2019-2020 | |
| Scpharmaceuticals INC. | $58.87 | 2025 | |
| Pfizer INC. | $37.12 | 2020 | |
| Shockwave Medical, INC | $31.67 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $26.44 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $22.00 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.76 | 2025 | Lifevest |
| Preventice Services, LLC | $16.32 | 2021 | |
| Inari Medical, INC. | $14.15 | 2020 | |
| Amarin Pharma, INC. | $14.03 | 2020 | |
| Cardiovascular Systems INC. | $13.46 | 2019 | |
| Alnylam Pharmaceuticals INC. | $13.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashraf Abusara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.